- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05705427
COMBAT HBV Feasibility Trial (COMBAT-HBV)
Forenkling af hepatitis B-pleje under graviditet ved at kombinere fødselsdosisvaccine og tenofovir: COMBAT HBV Feasibility Trial
This is a double-blind, randomized placebo-controlled trial (RCT) of a prophylaxis-for-all approach to prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV) in the Democratic Republic of Congo (DRC). HBV-infected pregnant women will be randomized to either receive tenofovir or placebo beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Women will be followed every 4-6 weeks throughout the prenatal and postpartum period to evaluate for side effects related to the medication. Infants will receive a birth-dose of HBV vaccine, ideally within 24 hours. Participants will be followed longitudinally through 6 months' postpartum.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The overall study design is a randomized, double-blind, placebo-controlled trial among two groups of mother-infant dyads: women who receive TDF vs placebo in late pregnancy and the postpartum period (beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum). While official World Health Organization (WHO) recommendations are to continue TDF at least through delivery, a range from delivery through 12 weeks' postpartum is possible; the investigators will continue therapy through 4 weeks' postpartum in this study. This feasibility trial will evaluate the acceptability, safety and preliminary effectiveness of a TDF-for-all approach to prevent MTCT of HBV in low-resource settings. HBsAg-positive pregnant women will be enrolled at 28-32 weeks' gestation, and will present for regular medication checks, with a study closeout visit at 24 weeks' postpartum. Study activities at monthly medication checks will include medication refills, assessment of adherence (via pill counts and verbal surveys), and evaluation for side effects. All infants will receive a birth-dose of HBV vaccine within 24 hours of life. MTCT of HBV will be defined as the proportion of infants with positive HBsAg testing at 6 months. This pilot study will provide preliminary data for sample size calculations, including safety and effectiveness data, to prepare for larger RCTs to determine the effectiveness of a tenofovir-for-all approach, as well as the added benefit of tenofovir over birth-dose vaccination.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Kinshasa, Den demokratiske republik Congo
- Université Protestant au Congo
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Pregnant women ≥18 years of age who present for routine prenatal care between 28-32 weeks' gestation and who test HBV-positive by point-of-care hepatitis B surface antigen test. Women must intend to seek maternity and postpartum care exclusively at one of the Kinshasa-based study maternity centers.
- Infants born to enrolled women will be included in the study
Exclusion Criteria:
- Individuals with abnormal creatinine by point-of-care testing
- Any woman who plans to move outside of Kinshasa Province during the study period.
- Any HIV-positive individual, determined by routine point-of-care screening at antenatal care visits
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Tenofovir disoproxil fumarate (TDF) arm
140 pregnant women in the experimental arm will receive tenofovir disoproxil fumarate (TDF) 300 milligrams (mg) daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine. |
Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
Andre navne:
All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
Andre navne:
|
|
Placebo komparator: Placebo arm
140 pregnant women in the placebo arm will receive a placebo pill daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine. |
All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
Andre navne:
Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety (Pregnant Women): Number of Women With Adverse Effects Related to Study Medications
Tidsramme: Up to study close-out visit, or up to 6 months postpartum
|
Safety of TDF prophylaxis in pregnant women, defined as the number of participants who experienced at least one adverse event (# mild adverse events [AEs], # moderate-to-severe AEs and # life-threatening AEs) and/or alanine aminotransferase elevation ≥ 5x upper limit of normal |
Up to study close-out visit, or up to 6 months postpartum
|
|
Safety (Infants): Number of Infants With Adverse Effects Related to Study Medications
Tidsramme: At delivery
|
Safety of hepatitis B birth-dose vaccine for infants, # of study medication related adverse events |
At delivery
|
|
Feasibility (Recruitment): Number of Eligible Participants Who Were Enrolled in the Study
Tidsramme: Up to study close-out visit, or up to 6 months postpartum
|
Recruitment is indicative of the number of pregnant women who are screened versus those actually enrolled in the study. |
Up to study close-out visit, or up to 6 months postpartum
|
|
Feasibility (Refusal): Number of Eligible Participants Who Refused to Enroll in the Study
Tidsramme: Screening until end of enrollment eligibility period, up to 32 weeks gestation
|
Refusal will be defined as the number of individuals who refuse enrollment upon initial recruitment. |
Screening until end of enrollment eligibility period, up to 32 weeks gestation
|
|
Feasibility (Withdrawal): Number of Enrolled Participants Who Withdraw From the Study
Tidsramme: Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
|
Withdrawal is indicative of the number of enrolled participants who choose not to continue study activities after having been enrolled. |
Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
|
|
Feasibility (Retention): Number of Enrolled Participants Who Remain in the Study Through 6 Months Postpartum
Tidsramme: Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
|
Retention is defined as the number of participants who remain in the study through the 6-month postpartum visit. |
Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
|
|
Feasibility (Maintenance): Mean Proportion of Study Visits Completed Per Maternal Participants
Tidsramme: Up to study close-out visit, or up to 6 months postpartum
|
Adherence to study visits and procedures among mothers, defined as the proportion of actual visits completed. The mean proportion of visits completed out of the total number of scheduled (or expected) study visits (i.e., up to eight possible visits) is reported. |
Up to study close-out visit, or up to 6 months postpartum
|
|
Acceptability (Lab Testing): Number of Mothers With Lab Testing Acceptability Scores >80%
Tidsramme: Up to study close-out visit, or up to 6 months postpartum
|
Number of mothers who report the process of undergoing lab draws as "acceptable" in the exit survey. Range 0-100%, with 0% being unacceptable and 100% being acceptable. |
Up to study close-out visit, or up to 6 months postpartum
|
|
Acceptability (Medication): Number of Mothers With Medication Acceptability Scores >80%
Tidsramme: Up to study close-out visit, or up to 6 months postpartum
|
Number of mothers who report the process of taking the study medication as "acceptable" in the exit survey. Range 0-100%, with 0% being unacceptable and 100% being acceptable. |
Up to study close-out visit, or up to 6 months postpartum
|
|
Preliminary Effectiveness: Number of Infants With HBV Positivity by Rapid Diagnostic Testing at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV
Tidsramme: Measured at 6 months after birth
|
Mother-to-child transmission of HBV is defined as HBsAg positivity in the infant at 6 months of life. |
Measured at 6 months after birth
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensitivity of the Hepatitis B Core-Related Antigen Test Among Maternal Participants
Tidsramme: Measured at Enrollment
|
Sensitivity will be defined as the number of true positive tests divided by the sum of the true positives and false negatives. |
Measured at Enrollment
|
|
Specificity of the Hepatitis B Core-Related Antigen Test
Tidsramme: Measured at Enrollment
|
Specificity will be defined as the number of true negative tests divided by the sum of the true negatives and the false positives. |
Measured at Enrollment
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Peyton Thompson, MD, MSCR, University of North Carolina, Chapel Hill
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Blodbårne infektioner
- Infektioner
- Virussygdomme
- Sygdomme i fordøjelsessystemet
- Leversygdomme
- Hepatitis, viral, menneskelig
- Overførbare sygdomme
- DNA-virusinfektioner
- Hepadnaviridae infektioner
- Hepatitis
- Hepatitis B
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Puriner
- Organophosphorforbindelser
- Organophosphonater
- Adenin
- Tenofovir
- Engerix-B
Andre undersøgelses-id-numre
- 22-1492
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Datasets will not be made publicly available because they contain protected health information. However, the authors will share de-identified participant data, alongside the study protocol, statistical analysis plan, and analytic code, upon reasonable request and with approval by an independent review committee (ie, learned intermediary). An executed Data Use/Sharing agreement with the University of North Carolina at Chapel Hill (UNC-CH) is required before data will be shared
IPD-delingstidsramme
Data will be available from 9 to 36 months after publication.
IPD-delingsadgangskriterier
Interested individuals can request de-identified data with approval from an independent review committee, which will be shared upon execution of a Data Use/Sharing Agreement with UNC-CH.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .